These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

49 related articles for article (PubMed ID: 7827127)

  • 21. Point mutations in apolipoprotein A-I mimic the phenotype observed in patients with classical lecithin:cholesterol acyltransferase deficiency.
    Chroni A; Duka A; Kan HY; Liu T; Zannis VI
    Biochemistry; 2005 Nov; 44(43):14353-66. PubMed ID: 16245952
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Natural mutations of apolipoprotein A-I impairing activation of lecithin:cholesterol acyltransferase.
    Hoang A; Huang W; Sasaki J; Sviridov D
    Biochim Biophys Acta; 2003 Feb; 1631(1):72-6. PubMed ID: 12573451
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cholesterol efflux potential of sera from mice expressing human cholesteryl ester transfer protein and/or human apolipoprotein AI.
    Atger V; de la Llera Moya M; Bamberger M; Francone O; Cosgrove P; Tall A; Walsh A; Moatti N; Rothblat G
    J Clin Invest; 1995 Dec; 96(6):2613-22. PubMed ID: 8675626
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Deletion of amino acids Glu146-->Arg160 in human apolipoprotein A-I (ApoA-ISeattle) alters lecithin:cholesterol acyltransferase activity and recruitment of cell phospholipid.
    Lindholm EM; Bielicki JK; Curtiss LK; Rubin EM; Forte TM
    Biochemistry; 1998 Apr; 37(14):4863-8. PubMed ID: 9538003
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Apolipoprotein A-I-containing lipoproteins in human umbilical cord blood. Relation to proapolipoprotein A-I and lecithin:cholesterol acyltransferase.
    Barkia A; Thiemann E; Czekelius P; Wiegel A; Leroy A; Fruchart JC; Steinmetz A
    Biol Neonate; 1991; 59(6):352-7. PubMed ID: 1908326
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cholesterol efflux, lecithin-cholesterol acyltransferase activity, and pre-beta particle formation by serum from human apolipoprotein A-I and apolipoprotein A-I/apolipoprotein A-II transgenic mice consistent with the latter being less effective for reverse cholesterol transport.
    Castro G; Nihoul LP; Dengremont C; de Geitère C; Delfly B; Tailleux A; Fievet C; Duverger N; Denèfle P; Fruchart JC; Rubin EM
    Biochemistry; 1997 Feb; 36(8):2243-9. PubMed ID: 9047326
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Structural and functional properties of natural and chemical variants of apolipoprotein A-I.
    Jonas A; von Eckardstein A; Churgay L; Mantulin WW; Assmann G
    Biochim Biophys Acta; 1993 Feb; 1166(2-3):202-10. PubMed ID: 8443238
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Accumulation of cholestatic lipoproteins in ANIT-treated human apolipoprotein A-I transgenic rats is diminished through dose-dependent apolipoprotein A-I activation of LCAT.
    Chisholm JW; Paterniti JR; Dolphin PJ
    Biochim Biophys Acta; 2000 Sep; 1487(2-3):145-54. PubMed ID: 11018467
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Truncation of the amino terminus of human apolipoprotein A-I substantially alters only the lipid-free conformation.
    Rogers DP; Brouillette CG; Engler JA; Tendian SW; Roberts L; Mishra VK; Anantharamaiah GM; Lund-Katz S; Phillips MC; Ray MJ
    Biochemistry; 1997 Jan; 36(2):288-300. PubMed ID: 9003180
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The lipid-free structure of apolipoprotein A-I: effects of amino-terminal deletions.
    Rogers DP; Roberts LM; Lebowitz J; Datta G; Anantharamaiah GM; Engler JA; Brouillette CG
    Biochemistry; 1998 Aug; 37(34):11714-25. PubMed ID: 9718294
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Coincubation of PON1, APO A1, and LCAT increases the time HDL is able to prevent LDL oxidation.
    Hine D; Mackness B; Mackness M
    IUBMB Life; 2012 Feb; 64(2):157-61. PubMed ID: 22184096
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Selectivity and contribution of lecithin: cholesterol acyltransferase to plasma cholesterol ester formation.
    Ueno K; Sakuma N; Kawaguchi M; Fujinami T; Okuyama H
    J Biochem; 1986 Feb; 99(2):541-7. PubMed ID: 3700364
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hydrolysis and transesterification of platelet-activating factor by lecithin-cholesterol acyltransferase.
    Liu M; Subbaiah PV
    Proc Natl Acad Sci U S A; 1994 Jun; 91(13):6035-9. PubMed ID: 8016111
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Overexpression of lecithin:cholesterol acyltransferase in transgenic rabbits prevents diet-induced atherosclerosis.
    Hoeg JM; Santamarina-Fojo S; Bérard AM; Cornhill JF; Herderick EE; Feldman SH; Haudenschild CC; Vaisman BL; Hoyt RF; Demosky SJ; Kauffman RD; Hazel CM; Marcovina SM; Brewer HB
    Proc Natl Acad Sci U S A; 1996 Oct; 93(21):11448-53. PubMed ID: 8876155
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Human apo A-I in transgenic mice is more efficient in activating lecithin:cholesterol acyltransferase than mouse apo A-I.
    Golder-Novoselsky E; Nichols AV; Rubin EM; Forte TM
    Biochim Biophys Acta; 1995 Jan; 1254(2):217-20. PubMed ID: 7827127
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression of human lecithin-cholesterol acyltransferase in transgenic mice. Effect of human apolipoprotein AI and human apolipoprotein all on plasma lipoprotein cholesterol metabolism.
    Francone OL; Gong EL; Ng DS; Fielding CJ; Rubin EM
    J Clin Invest; 1995 Sep; 96(3):1440-8. PubMed ID: 7657816
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interaction of rat lecithin-cholesterol acyltransferase with rat apolipoprotein A-I and with lecithin-cholesterol vesicles.
    Furukawa Y; Urano T; Hida Y; Itoh H; Takahashi C; Kimura S
    J Biochem; 1992 Mar; 111(3):413-8. PubMed ID: 1587806
    [TBL] [Abstract][Full Text] [Related]  

  • 38. DYRK1A overexpression decreases plasma lecithin:cholesterol acyltransferase activity and apolipoprotein A-I levels.
    Tlili A; Noll C; Middendorp S; Duchon A; Jouan M; Benabou E; Hérault Y; Paul JL; Delabar JM; Janel N
    Mol Genet Metab; 2013 Nov; 110(3):371-7. PubMed ID: 23920041
    [TBL] [Abstract][Full Text] [Related]  

  • 39. LCAT activation properties of apo A-I CNBr fragments and conversion of discoidal complexes into spherical particles.
    Vanloo B; Taveirne J; Baert J; Lorent G; Lins L; Ruyschaert JM; Rosseneu M
    Biochim Biophys Acta; 1992 Oct; 1128(2-3):258-66. PubMed ID: 1420299
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Reverse cholesterol transport and use of transgenic mice and rabbits to reveal candidate genes for protection against atherosclerosis].
    Fruchart JC; Duriez P
    Bull Acad Natl Med; 1998; 182(2):233-47; discussion 247-9. PubMed ID: 9648340
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.